<DOC>
	<DOCNO>NCT00003928</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well gemcitabine cisplatin work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Cisplatin Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess response rate patient metastatic renal cell carcinoma treat gemcitabine cisplatin . - Assess toxicity regimen patient . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 cisplatin IV 60 minute day 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 4 month . PROJECTED ACCRUAL : Approximately 29-38 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic renal cell carcinoma No brain metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm^3 Hematocrit least 30 % Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 1.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled hypertension No myocardial infarction within past 8 week Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 5 year except nonmelanomatous skin cancer , carcinoma situ cervix , prostate intraepithelial neoplasia , superficial bladder cancer No significant psychiatric disease No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No 2 prior biologic response modifier regimens No concurrent biologic therapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow measurable disease outside radiation port At least 28 day since prior radiotherapy No concurrent radiotherapy Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>